

- lymphoma. *J Nucl Med* 2000; 41: 952–958.
6. **Gordon LI, Witzig TE, Wiseman GA, et al.** Yttrium 90 ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory low-grade non-Hodgkin's lymphoma. *Sem Oncol* 2002; 29 (Suppl 2): 87–92.
  7. **Witzig TE, White CA, Wiseman GA, Gordon LI, Emmanouilides C, Raubitschek A, et al.** Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20+ B-cell non-Hodgkin's lymphoma. *J Clin Oncol* 1999; 17: 3793–3803.
  8. **Witzig TE, Gordon LI, Cabanillas F, Czuczman MS, Emmanouilides C, Joyce R, et al.** Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. *J Clin Oncol* 2002; 20: 2453–2463.
  9. **Gordon LI, Molina A, Witzig T, Emmanouilides C, Raubitschek A, Darif M, et al.** Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of a phase 1/2 study. *Blood* 2004; 103: 4429–4431.
  10. **Ansell SM, Ristow KM, Haneremann TM, et al.** Subsequent chemotherapy regimens are well tolerated after radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for non-Hodgkin's lymphoma. *J Clin Oncol* 2002; 20: 3885–3890.
  11. **Emmanouilides C, Witzig TE, Gordon LI, et al.** Treatment with yttrium 90 ibritumomab tiuxetan at early relapse is safe and effective in patients with previously treated B-cell non-Hodgkin's lymphoma. *Leuk Lymphoma* 2006; 47: 629–636.
  12. **Jacobs SA, Vidnovic N, Joyce J, et al.** Full-dose 90Y ibritumomab tiuxetan therapy is safe in patients with prior myeloablative chemotherapy. *Clin Cancer Res* 2005; 11: 7146–7150.
  13. **Shipp MA, Harrington DP, Anderson JR, et al.** A predictive model for aggressive non-Hodgkin's lymphoma. *N Engl J Med* 1993; 329: 987–994.
  14. **Solal-Céligny P, Roy P, Colombat P, et al.** Follicular lymphoma prognostic index. *Blood* 2004; 104: 1258–1265.
  15. **Cheson BD, Horning SJ, Coiffier B, et al.** Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. *J Clin Oncol* 1999; 17: 1244–1253.
  16. **Shibley DL, Spigel DR, Carell DL, et al.** Phase II trial of rituximab and short duration chemotherapy followed by 90Y ibritumomab tiuxetan as first-line treatment for patients with follicular lymphoma: a Minnie Pearl Cancer Research Network phase II trial. *J Clin Oncol ASCO Annual Meeting Proceedings* 2004; 22 (Suppl 14): 6519.
  17. **Jurczak WJ, Szostek MS, Giza AG, et al.** Consolidation of chemotherapy response in mantle cell lymphoma (MCL) patients with 90Y-ibritumomab tiuxetan (90Y-Zevalin®) radioimmunotherapy (RIT). *Haematologica* 2006; 91 (Suppl. 1): 188.
  18. **Dreyling M, Trümper L, von Schilling C, et al.** Results of national consensus workshop: therapeutic algorithm in patients with follicular lymphoma – role of radioimmunotherapy. *Ann Hematol* 2007; 86: 81–87.
  19. **Rose AL, Smith B, Maloney DG.** Glucocorticoids and rituximab in vitro: synergistic direct antiproliferative and apoptotic effects. *Blood* 2002; 100: 1765–1773.

Podpořeno grantem IGA MZ ČR No. NR/9502-3  
a VZ MŠM 619 895 9205

MUDr. Tomáš Papajík, CSc.  
Hemato-onkologická klinika LF UP a FN Olomouc  
I. P. Pavlova 6  
775 20 Olomouc  
e-mail: tomas.papajik@fnol.cz

## GRATULUJEME

Ve druhé polovině roku 2007 někteří členové Společnosti pro transfuzní lékařství ČLS JEP oslavili významná životní výročí. Všem kolegyním a kolegům gratulujeme a přejeme jim další cestu životem, naplněnou zdravím, štěstím a životní pohodou.

MUDr. Banzetová Helena  
MUDr. Černohorská Jitka  
MUDr. Fenclová Eva  
prof. MUDr. Indrák Karel, DrSc.  
Knopová Jitka  
MUDr. Jitka Mačalová  
doc. MUDr. Neuwirthová Radana, CSc.  
Tlapáková Eva  
MUDr. Tomancová Marie  
MUDr. Valentová Kamila  
Alena Vašková  
MUDr. Zvarová Marta

*Redakční rada časopisu Transfuze a hematologie dnes, výbor STL*